Imperial College London
Alternate

ProfessorMartaBoffito

Faculty of Medicine, Department of Infectious Disease

Professor of Practice
 
 
 
//

Contact

 

+44 (0)20 3315 6148m.boffito

 
 
//

Location

 

St StephensChelsea and Westminster Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Randell:2010:10.3851/IMP1675,
author = {Randell, PA and Jackson, AG and Boffito, M and Back, DJ and Tjia, JF and Taylor, J and Mandalia, S and Moyle, GJ},
doi = {10.3851/IMP1675},
journal = {Antivir Ther},
pages = {1125--1132},
title = {Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.},
url = {http://dx.doi.org/10.3851/IMP1675},
volume = {15},
year = {2010}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Antiretroviral therapy is associated with metabolic complications, including dyslipidaemia, body fat changes and insulin resistance. Healthy volunteer studies have demonstrated a decrease in glucose disposal associated with dosing with specific antiretrovirals. METHODS: HIV-type-1-positive male participants were randomized to receive tenofovir disoproxil fumarate and lamivudine, with either fosamprenavir (FPV)/ritonavir or lopinavir (LPV)/ritonavir twice daily. A hyperinsulinaemic euglycaemic clamp was performed at baseline and at 2 weeks after commencing treatment. The homeostasis model assessment index for insulin resistance (HOMA-IR) was also calculated at these time points. Changes in lipids and lipoprotein subfractions (by nuclear magnetic resonance spectroscopy) were assessed. A pharmacokinetic assessment was undertaken at week 2. RESULTS: A total of 27 participants were enrolled. There was no significant change in whole-body insulin sensitivity or HOMA-IR from baseline or between groups. Total cholesterol increased significantly, by 6.6% with FPV and 10.9% with LPV. The changes in lipids and lipoprotein subfractions were similar between groups with increases in triglycerides, very low-density lipoprotein (VLDL) and chylomicrons, and low-density lipoprotein (LDL) particles. Although the total high-density lipoprotein (HDL) particles were not significantly altered, a decrease in small HDL particles was seen. Changes in VLDL and chylomicron particles in both groups and triglycerides and small HDL particles in the LPV group were statistically significant. CONCLUSIONS: In HIV-type-1-positive men initiating antiretroviral therapy with FPV- or LPV-based regimens, there were no significant changes in whole-body insulin sensitivity after 2 weeks. A proatherogenic lipid profile characterized by increases in triglycerides, VLDL and chylomicron particles and LDL particles, and a decrease in small HDL particles, was observed in both groups.
AU  - Randell,PA
AU  - Jackson,AG
AU  - Boffito,M
AU  - Back,DJ
AU  - Tjia,JF
AU  - Taylor,J
AU  - Mandalia,S
AU  - Moyle,GJ
DO  - 10.3851/IMP1675
EP  - 1132
PY  - 2010///
SP  - 1125
TI  - Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
T2  - Antivir Ther
UR  - http://dx.doi.org/10.3851/IMP1675
UR  - https://www.ncbi.nlm.nih.gov/pubmed/21149919
VL  - 15
ER  -
Download